Can Asprosin be Used as a Diagnostic Biomarker for Non-Alcoholic Fatty Liver Disease in Obese Children?

This publication has 26 references indexed in Scilit:

• 2. Glycaemic control assessment and targets in type 2 diabetes
  Diabetes Research and Clinical Practice, 2025
• Increased asprosin is associated with non-alcoholic fatty liver disease in children with obesity
  World Journal of Pediatrics, 2021
• Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: Comprehensive review of preclinical and clinical evidence
  Cytokine & Growth Factor Reviews, 2021
• Combination of asprosin and adiponectin as a novel marker for diagnosing non-alcoholic fatty liver disease
  Cytokine, 2020
• Adipokines as novel biomarkers of cardio-metabolic disorders
  Clinica Chimica Acta, 2020
• Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation
  Molecular and Cellular Endocrinology, 2019
• Asprosin, a Fasting-Induced Glucogenic Protein Hormone
  Cell, 2016
• Circulating betatrophin concentration is negatively correlated with insulin resistance in obese children and adolescents
  Diabetes Research and Clinical Practice, 2016
• Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001
  JAMA, 2003
• Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
  Diabetologia, 1985